Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia
Open accessAbstract
Therapy-related myelodysplastic syndromes and acute myelogenous leukemia comprise a poor-risk subset of myelodysplastic syndromes and acute myelogenous leukemia. Large-scale mutation profiling efforts in de novo myelodysplastic syndromes have identified mutations that correlate with clinical features, but such mutations have not been investigated in therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Genomic DNA from 38 patient samples were subjected to high throughput polymerase chain reaction and sequenced for TP53, TET2, DNMT3A, ASXL1, IDH1, IDH2, EZH2, EED, SUZ12, RBBP4, SRSF2, U2AF35, and SF3B1. We identified somatic mutations in 16 of 38 (42%) patients. TP53 mutations were the most common lesion, detected in 8 of 38 (21%) patients, followed by TET2 in 4 of 38 (10.5%). Cases with a TP53 mutation or loss of the TP53 locus had a worse overall survival compared to those with wild-type TP53 (8.8 vs. 37.4 months; P=0.0035).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
t-AML differs from de novo AML by a higher incidence of TP53 mutations, abnormalities of chromosomes 5 or 7, complex cytogenetics, and a reduced response to chemotherapy.
“There are several features that distinguish t-AML from de novo AML including a higher incidence of TP53 mutations2,3, abnormalities of chromosomes 5 or 7, complex cytogenetics, and a reduced response to chemotherapy4.”
From Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia (2015) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933 · see citing works
WHO classification of haematolymphoid tumours
Gaillard, F., & Gerstenmaier, J. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,763 · see citing works
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029 · see citing works
<i>DNMT3A</i> Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983 · see citing works
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,936 · see citing works
Self-citationClinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627 · see citing works
Self-citationSomatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222 · see citing works
Smith, S. M., Beau, M. M. L., Huo, D., Karrison, T. G., Sobecks, R. M., Anastasi, J., Vardiman, J. W., Rowley, J. D., & Larson, R. A. (2003) · Blood · doi:10.1182/blood-2002-11-3343 · Cited by 681 · see citing works
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
Walter, M. J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.44 · Cited by 527 · see citing works
Itzykson, R., Kosmider, O., Cluzeau, T., Mas, V. M., Dreyfus, F., Beyne‐Rauzy, O., Quesnel, B., Vey, N., Gelsi‐Boyer, V., Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 470 · see citing works
Gaidzik, V. I., Bullinger, L., Schlenk, R. F., Zimmermann, A., Röck, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7926 · Cited by 454 · see citing works
Rowley, J., Golomb, H., & Vardiman, J. (1981) · Blood · doi:10.1182/blood.v58.4.759.759 · Cited by 440 · see citing works
Thol, F. R., Kade, S., Schlarmann, C., Löffeld, P., Morgan, M. A., Krauter, J., Włodarski, M. W., Kölking, B., Wichmann, M., Görlich, K., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399337 · Cited by 420 · see citing works
Therapy-Related Myeloid Leukemia
Godley, L. A., & Larson, R. A. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.012 · Cited by 347 · see citing works
Metzeler, K. H., Maharry, K. S., Radmacher, M. D., Mrózek, K., Margeson, D., Becker, H., Curfman, J. P., Holland, K. B., Schwind, S., Whitman, S. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7742 · Cited by 316 · see citing works
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308 · see citing works
Smith, R. E., Bryant, J., DeCillis, A. P., & Anderson, S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.114 · Cited by 299 · see citing works
Haferlach, C., Dicker, F., Herholz, H., Schnittger, S., Kern, W., & Haferlach, T. (2008) · Leukemia · doi:10.1038/leu.2008.143 · Cited by 247 · see citing works
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T., & Christiansen, D. H. (2008) · Leukemia · doi:10.1038/sj.leu.2405078 · Cited by 230 · see citing works
Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients
Armitage, J. O., Carbone, P. P., Connors, J. M., Levine, A. M., Bennett, J. M., & Kroll, S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.113 · Cited by 224 · see citing works
Kröger, N. M., Brand, R., van Biezen, A., Zander, A., Dierlamm, J., Niederwieser, D. W., Devergié, A., Ruutu, T., Cornish, J., Ljungman, P. T., et al. (2009) · Haematologica · doi:10.3324/haematol.2008.000927 · Cited by 121 · see citing works
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., & on behalf of Genomics of AML Program Project Grant (2011) · Blood · doi:10.1182/blood.v118.21.sci-31.sci-31 · Cited by 119 · see citing works
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
McCullough, A. J. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.11.023 · Cited by 77 · see citing works
Armand, P. A., Deeg, H. J., Kim, H. T., Lee, H., Armistead, P. M., Lima, M. J. G. D., Gupta, V. K., & Soiffer, R. J. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.253 · Cited by 44 · see citing works
Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato‐Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Blood · doi:10.1182/blood.v118.21.458.458 · Cited by 39 · see citing works
Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes
Klimek, V. M., Dolezal, E. K., Tees, M. T., Devlin, S. M., Stein, K. F., Romero, A., & Nimer, S. D. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.04.025 · Cited by 30 · see citing works
Self-citationRowley, J., Golomb, H., & Vardiman, J. (1981) · Blood · doi:10.1182/blood.v58.4.759.bloodjournal584759 · Cited by 29 · see citing works
Roos, A. J. D., Deeg, H. J., & Davis, S. (2007) · Cancer Causes & Control · doi:10.1007/s10552-007-9060-2 · Cited by 25 · see citing works
Arceci, R. J. (2012) · Yearbook of Oncology · doi:10.1016/j.yonc.2012.07.010 · Cited by 20 · see citing works
Yokoyama, H., Mori, S., Kobayashi, Y., Kurosawa, S., Saito, B., Fuji, S., Maruyama, D., Azuma, T., Kim, S. W., Watanabe, T., et al. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0640-7 · Cited by 6 · see citing works
Arceci, R. J. (2011) · Yearbook of Oncology · doi:10.1016/j.yonc.2011.07.028 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,780 · see citing works
Self-citationRole of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892 · see citing works
Advances in acute myeloid leukemia
Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 455 · see citing works
Therapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Beau, M. M. L. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.60 · Cited by 422 · see citing works
Gillis, N. K., Ball, M., Zhang, Q., Ma, Z., Zhao, Y., Yoder, S. J., Balasis, M. E., Mesa, T. E., Sallman, D. A., Lancet, J. E., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30627-1 · Cited by 317 · see citing works
Churpek, J. E., Marquez, R., Neistadt, B., Claussen, K., Lee, M. K., Churpek, M. M., Huo, D., Weiner, H., Banerjee, M., Godley, L. A., et al. (2015) · Cancer · doi:10.1002/cncr.29615 · Cited by 170 · see citing works
Splicing factor mutations and cancer
Yoshida, K., & Ogawa, S. (2014) · WIREs RNA · doi:10.1002/wrna.1222 · Cited by 155 · see citing works
Ok, C. Y., Patel, K. P., Garcia‐Manero, G., Routbort, M. J., Peng, J., Tang, G., Goswami, M., Young, K. H., Singh, R. R., Medeiros, L. J., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0139-z · Cited by 141 · see citing works
Ok, C. Y., Patel, K. P., Garcia‐Manero, G., Routbort, M. J., Fu, B., Tang, G., Goswami, M., Singh, R. R., Kanagal‐Shamanna, R., Pierce, S. A., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.12.006 · Cited by 128 · see citing works
Fianchi, L., Pagano, L., Piciocchi, A., Candoni, A., Gaïdano, G., Breccia, M., Criscuolo, M., Specchia, G., Pogliani, E. M., Maurillo, L., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23966 · Cited by 124 · see citing works
Genetic and epigenetic determinants of AML pathogenesis
Cai, S. F., & Levine, R. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.08.001 · Cited by 114 · see citing works
Self-citationEarly Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer
Phallen, J. A., Leal, A., Woodward, B. D., Forde, P. M., Naidoo, J., Marrone, K. A., Brahmer, J. R., Fiksel, J., Medina, J. E., Cristiano, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1082 · Cited by 107 · see citing works
Nishida, Y., Maeda, A., Kim, M. J., Cao, L., Kubota, Y., Ishizawa, J., Al-Rawi, A., Kato, Y., Iwama, A., Fujisawa, M., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.8 · Cited by 96 · see citing works
Diagnosis and treatment of therapy-related acute myeloid leukemia
Strickland, S. A., & Vey, N. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103607 · Cited by 92 · see citing works
Stoddart, A., Fernald, A. A., Wang, J., Davis, E. M., Karrison, T. G., Anastasi, J., & Beau, M. M. L. (2014) · Blood · doi:10.1182/blood-2013-07-517953 · Cited by 88 · see citing works
Kuendgen, A., Nomdedéu, M., Tuechler, H., Garcia‐Manero, G., Komrokji, R. S., Sekeres, M. A., Porta, M. G. D., Cazzola, M., Dezern, A. E., Roboz, G. J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0917-7 · Cited by 83 · see citing works
TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
Molica, M., Mazzone, C., Niscola, P., & de Fabritiis, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.610820 · Cited by 71 · see citing works
Visconte, V., Tiu, R. V., & Rogers, H. J. (2014) · Blood Research · doi:10.5045/br.2014.49.4.216 · Cited by 71 · see citing works
Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Heuser, M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.24 · Cited by 64 · see citing works
Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., Feng, J., Wang, P. P.-S., Babic, M., Parker, W. T., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0479-8 · Cited by 62 · see citing works
Nilsson, C. C., Linde, F., Hulegårdh, E., Garelius, H. G., Lazarević, V., Antunović, P., Cammenga, J., Deneberg, S., Eriksson, A., Jädersten, M., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281233 · Cited by 60 · see citing works
Poiré, X., Labopin, M., Maertens, J. A., Yakoub‐Agha, I., Blaise, D., Ifrah, N., Socié, G., Gedde-Dhal, T., Schaap, N. P., Cornelissen, J. J., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0393-3 · Cited by 59 · see citing works
MDS prognostic scoring systems – Past, present, and future
Jonas, B. A., & Greenberg, P. L. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.11.001 · Cited by 53 · see citing works
Cleven, A. H. G., Nardi, V., Ok, C. Y., Goswami, M., Cin, P. D., Zheng, Z., Iafrate, A. J., Hamid, M. A. A., Wang, S. A., & Hasserjian, R. P. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.153 · Cited by 50 · see citing works
Pharmacological activation of wild-type p53 in the therapy of leukemia
Kojima, K., Ishizawa, J., & Andreeff, M. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.05.014 · Cited by 52 · see citing works
Second malignancies in multiple myeloma; emerging patterns and future directions
Maclachlan, K. H., Diamond, B. T., Maura, F., Hillengaß, J., Turesson, I., Landgren, O., & Kazandjian, D. G. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101144 · Cited by 48 · see citing works
Jacoby, M. A., Pizarro, R. E. D. J., Shao, J., Koboldt, D. C., Fulton, R. S., Zhou, G., Wilson, R. K., & Walter, M. J. (2013) · Leukemia · doi:10.1038/leu.2013.368 · Cited by 42 · see citing works
Yokota, A., Huo, L., Lan, F., Wu, J., & Huang, G. (2020) · PubMed Central · doi:10.14348/molcells.2019.0252 · Cited by 45 · see citing works
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
Csizmar, C. M., Saliba, A. N., Swisher, E. M., & Kaufmann, S. H. (2021) · Cancers · doi:10.3390/cancers13246385 · Cited by 45 · see citing works
Incidence and survival of therapy related myeloid neoplasm in United States
Murthy, G. S. G., Hamadani, M., Dhakal, B., Hari, P., & Atallah, E. L. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.07.013 · Cited by 42 · see citing works
Integrating mutation variant allele frequency into clinical practice in myeloid malignancies
Sallman, D. A., & Padron, E. (2016) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2016.04.003 · Cited by 38 · see citing works
Eastmond, D. A., Keshava, N., & Sonawane, B. R. (2014) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.04.001 · Cited by 42 · see citing works
Marçais, A., Lhermitte, L., Artesi, M., Laurent, C., Durkin, K., Hahaut, V., Rosewick, N., Suárez, F., Sibon, D., Cheminant, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0900-3 · Cited by 40 · see citing works
Kanagal‐Shamanna, R., Singh, R. R., Routbort, M. J., Patel, K. P., Medeiros, L. J., & Luthra, R. (2016) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1142374 · Cited by 38 · see citing works
Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin
Wang, Y., Liu, Y., Bailey, C., Zhang, H., He, M., Sun, D., Zhang, P., Parkin, B., Baer, M. R., Zheng, P., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1201-z · Cited by 38 · see citing works
An MDM2 degrader for treatment of acute leukemias
Marcellino, B. K., Yang, X., Kanıskan, H. Ü., Brady, C., Chen, H., Chen, K., Qiu, X., Clementelli, C., Herschbein, L., Li, Z., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01735-6 · Cited by 36 · see citing works
Self-citationGenetic and epigenetic pathways in myelodysplastic syndromes: A brief overview
Jhanwar, S. C. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.11.002 · Cited by 36 · see citing works
Therapy-related myeloid neoplasms
Ganser, A., & Heuser, M. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000316 · Cited by 35 · see citing works
Nybakken, G. E., & Bagg, A. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.11.005 · Cited by 35 · see citing works
Therapy-related myeloid neoplasms: clinical perspectives
Fianchi, L., Criscuolo, M., Fabiani, E., Falconi, G., Maraglino, A. M. E., Voso, M. T., & Pagano, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s101333 · Cited by 35 · see citing works
Stoddart, A., Wang, J., Fernald, A. A., Davis, E. M., Johnson, C. R., Hu, C., Cheng, J. X., McNerney, M. E., & Beau, M. M. L. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-19-0028 · Cited by 35 · see citing works
Preexisting TP53 mutation in therapy-related acute myeloid leukemia
Schulz, E., Kashofer, K., Heitzer, E., Mhatre, K. N., Speicher, M. R., Höefler, G., & Sill, H. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2191-0 · Cited by 34 · see citing works
New Therapeutic Strategies for Adult Acute Myeloid Leukemia
Ishii, H., & Yano, S. (2022) · Cancers · doi:10.3390/cancers14112806 · Cited by 33 · see citing works
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia
Khan, N., Hantel, A., Knoebel, R. W., Artz, A. S., Larson, R. A., Godley, L. A., Thirman, M. J., Liu, H., Churpek, J. E., King, D. P., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1289524 · Cited by 32 · see citing works
Li, Y., Xue, Z., Dong, X., Liu, Q., Liu, Z., Li, H., Xing, H., Xu, Y., Tang, K., Tian, Z., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.11.007 · Cited by 31 · see citing works
Therapy-Related Myeloid Neoplasms
Bueso-Ramos, C., Kanagal‐Shamanna, R., Routbort, M. J., & Hanson, C. A. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpu1jo2lytwuav · Cited by 30 · see citing works
Uncoding the genetic heterogeneity of myelodysplastic syndrome
Lindsley, R. C. (2017) · Hematology · doi:10.1182/asheducation-2017.1.447 · Cited by 29 · see citing works
Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
Marcellino, B. K., Farnoud, N. R., Cassinat, B., Lü, M., Verger, E., McGovern, E. M., Patel, M. A., Medina-Martinez, J. S., Levine, M. F., Ossa, J. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002379 · Cited by 29 · see citing works
Clonal evolution in therapy-related neoplasms
Fabiani, E., Falconi, G., Fianchi, L., Criscuolo, M., Ottone, T., Cicconi, L., Hohaus, S., Sica, S., Postorino, M., Neri, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14509 · Cited by 29 · see citing works
Khalife‐Hachem, S., Saleh, K., Pasquier, F., Willekens, C., Tarabay, A., Antoun, L., Grinda, T., Castilla‐Llorente, C., Duchmann, M., Quivoron, C., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000632 · Cited by 26 · see citing works
p53 biology and reactivation for improved therapy in MDS and AML
Zawacka‐Pankau, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00579-9 · Cited by 25 · see citing works
Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Parkin, B. L., Ouillette, P. D., Yildiz, M., Saiya-Cork, K., Shedden, K., & Malek, S. N. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0921 · Cited by 25 · see citing works
Wang, W., Routbort, M. J., Tang, Z., Ok, C. Y., Patel, K. P., Daver, N. G., Garcia‐Manero, G., Medeiros, L. J., & Wang, S. A. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12971 · Cited by 24 · see citing works
Stoddart, A., Wang, J., Fernald, A. A., Karrison, T. G., Anastasi, J., & Beau, M. M. L. (2013) · Blood · doi:10.1182/blood-2013-05-506568 · Cited by 23 · see citing works
Lu, E. P., McLellan, M. D., Ding, L., Fulton, R. S., Mardis, E. R., Wilson, R. K., Miller, C. A., Westervelt, P., DiPersio, J. F., Link, D. C., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582551 · Cited by 23 · see citing works
Gramegna, D., Bertoli, D., Cattaneo, C. M., Almici, C., Re, A., Belotti, A., Borlenghi, E., Lanzi, G., Archetti, S., Verardi, R., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04806-x · Cited by 20 · see citing works
TP53 in AML and MDS: The new (old) kid on the block
Marks, J. A., Wang, X., Fenu, E. M., Bagg, A., & Lai, C. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101055 · Cited by 19 · see citing works
Ahmadi, S. E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S. M., Shabannezhad, A., Jaafari, N., & Safa, M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00676-9 · Cited by 22 · see citing works
Mutation analysis of therapy-related myeloid neoplasms
Nishiyama, T., Ishikawa, Y., Kawashima, N., Akashi, A., Adachi, Y., Hattori, H., Ushijima, Y., & Kiyoi, H. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.02.006 · Cited by 19 · see citing works
Therapy-related myeloid neoplasms
Klimek, V. M., & Tray, N. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000222 · Cited by 17 · see citing works
Self-citationClinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome
Chua, C. C., Fleming, S. A., & Wei, A. H. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.007 · Cited by 17 · see citing works
Sasaki, K., Jabbour, E. J., Cortes, J. E., Kadia, T. M., Garcia‐Manero, G., Borthakur, G. M., Jain, P., Pierce, S. A., Daver, N. G., Takahashi, K., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.015 · Cited by 17 · see citing works
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms
Fabiani, E., Falconi, G., Fianchi, L., Criscuolo, M., Leone, G. G. M., & Voso, M. T. (2014) · Haematologica · doi:10.3324/haematol.2014.108159 · Cited by 16 · see citing works
Therapeutic Vulnerabilities of Transcription Factors in AML
Khan, I., Eklund, E. A., & Gartel, A. L. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0115 · Cited by 14 · see citing works
Dao, K.-H. T. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.09.006 · Cited by 15 · see citing works
Herold, S., Sockel, K., Sayehli, C. M., Herbst, R., Dührsen, U., Oelschlägel, U., Böttner, A., Hindahl, H., Kullmer, J., Helas, S., et al. (2017) · Leukemia · doi:10.1038/leu.2017.217 · Cited by 15 · see citing works
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
Vicente, A. T. S., & Salvador, J. A. R. (2024) · MedComm · doi:10.1002/mco2.575 · Cited by 14 · see citing works
Cho, Y., Jang, S., Seo, E., Park, C., Chi, H., Kim, D., Lee, J., Lee, J., Lee, K., Koh, K., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.995648 · Cited by 14 · see citing works
Self-citationArber, D. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47913-4.00014-8 · Cited by 14 · see citing works
Cantu, M. D., Kanagal‐Shamanna, R., Wang, S. A., Kadia, T. M., Bueso-Ramos, C., Patel, S. S., Geyer, J. T., Tam, W., Madanat, Y. F., Li, P., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00400 · Cited by 14 · see citing works
Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
Bertoli, S., Sterin, A., Tavitian, S., Obéric, L., Ysebaert, L., Bouabdallah, R., Vergez, F., Sarry, A., Bérard, E., Huguet, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13262 · Cited by 14 · see citing works
MGMT promoter methylation as a potential prognostic marker for acute leukemia
Sobieszkoda, D., Czech, J., Gabło, N., Kopańska, M., Tabarkiewicz, J., Kołacińska, A., Robak, T., & Zawlik, I. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.71067 · Cited by 14 · see citing works
A monocentric retrospective study of 138 therapy-related myeloid neoplasms
Claerhout, H., Lierman, E., Michaux, L., Verhoef, G. E. G., & Boeckx, N. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3462-y · Cited by 14 · see citing works
LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia
Hu, T., Zhang, Y., Yang, T., He, Q., & Zhao, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.795820 · Cited by 14 · see citing works
Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression
Auerbach, S., Puka, B., Golla, U., & Chachoua, I. (2024) · Life · doi:10.3390/life14030309 · Cited by 13 · see citing works
Predicting therapy-related myeloid neoplasms—and preventing them?
Steensma, D. P. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30622-2 · Cited by 13 · see citing works
Genetic Pathway in the Pathogenesis of Therapy-Related Myeloid Neoplasms: A Literature Review
Tiruneh, T., Enawgaw, B., & Shiferaw, E. (2020) · Oncology and Therapy · doi:10.1007/s40487-020-00111-7 · Cited by 13 · see citing works
Analysis of Mutational Hotspots in Routinely Processed Bone Marrow Trephines by Pyrosequencing®
Bartels, S., & Lehmann, U. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2715-9_8 · Cited by 12 · see citing works
Therapy-related myeloid neoplasms with different latencies: a detailed clinicopathologic analysis
Liu, Y., Illar, G. M., Amri, R. A., Canady, B. C., Rea, B. A., Yatsenko, S. A., & Geyer, J. T. (2021) · Modern Pathology · doi:10.1038/s41379-021-00958-9 · Cited by 12 · see citing works
Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014
Feldman, E. J. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.031 · Cited by 12 · see citing works
Werneth, C. M., Patel, Z. S., Thompson, M. S., Blattnig, S. R., & Huff, J. L. (2024) · Communications Medicine · doi:10.1038/s43856-023-00408-4 · Cited by 11 · see citing works
Fleenor, C. J., Higa, K. C., Weil, M. M., & DeGregori, J. V. (2015) · Radiation Research · doi:10.1667/rr14147.1 · Cited by 11 · see citing works
Calleja, A., Yun, S., Moreilhon, C., Karsenti, J. M., Gastaud, L., Mannone, L., Komrokji, R. S., Ali, N. E. A., Dadone-Montaudie, B., Robert, G., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13390 · Cited by 11 · see citing works
De Novo myelodysplastic syndromes in patients 20–50 years old are enriched for adverse risk features
Epstein-Peterson, Z. D., Spitzer, B. G., Derkach, A., Arango, J. E., McCarter, J. G. W., Medina-Martinez, J. S., McGovern, E. M., Farnoud, N. R., Levine, R. L., & Tallman, M. S. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106857 · Cited by 11 · see citing works
Self-citationRofes, P., Castillo-Manzano, C., Menéndez, M., Teulé, À., Iglesias, S. L., Munté, E., Ramos-Muntada, M., Gómez, C., Tornero, E., Darder, E., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01429-5 · Cited by 10 · see citing works
Hong, K. T., Choi, J. Y., Hong, C. R., Kang, H. J., Park, K. D., & Shin, H. Y. (2017) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001019 · Cited by 10 · see citing works
The Progress of Next Generation Sequencing in Assessment of Myeloid Malinancies
Puyan, F. Ö., & Alkan, S. (2018) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2018.2018.1195 · Cited by 10 · see citing works
Stem cell damage after chemotherapy- can we do better?
Tang, J., Zhu, N., Rao, S., & Carlson, K.-S. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.001 · Cited by 9 · see citing works
Aqil, B., Gao, J., Stalling, M., SUKHANOVA, M. J., Duncavage, E. J., Lu, X. Y., Wolniak, K. L., Kreisel, F. H. C., & Yaseen, N. R. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab178 · Cited by 9 · see citing works
Hong, M., Hao, S., Patel, K. P., Kantarjian, H. M., Garcia‐Manero, G., Yin, C. C., Medeiros, L. J., Lin, P., & Lu, X. Y. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2016.04.001 · Cited by 9 · see citing works
Nampoothiri, R. V., Law, A., Lam, W., Chen, C. C. L., Al‐Shaibani, Z., Loach, D., Michelis, F. V., Kim, D. D. H., Mattsson, J., Kumar, R., et al. (2021) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2021.03.003 · Cited by 9 · see citing works
Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?
Madanat, Y. F., & Gerds, A. T. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.011 · Cited by 8 · see citing works
The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis
Fullin, J., Topçu, E., Zielińska, K. A., Schimmer, R. R., Klemm, N., Koch, C., Caiado, F., Lock, M., Doerdelmann, C., Bühler, M. M., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02839-5 · Cited by 8 · see citing works
Parmar, K., Kundu, R., Maiti, A., & Ball, S. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107546 · Cited by 7 · see citing works
Pourhassan, H., Tinajero, J., Ma, H., Jackson, R., Pillai, R. K., Ngo, D., Agrawal, V., Koller, P., Ball, B. J., Blackmon, A. L., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20260 · Cited by 5 · see citing works
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
Testa, U., Castelli, G., & Pelosi, E. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.038 · Cited by 5 · see citing works
Ma, J., & Wang, Y. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2329132 · Cited by 5 · see citing works
Evaluating targeted therapies in older patients with TP53 -mutated AML
Sabile, J. M. G., Swords, R. T., & Tyner, J. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2344057 · Cited by 4 · see citing works
Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms
Jahn, J., Diamond, B. T., Hsu, J., Montoya, S., Totiger, T. M., Landgren, O., Maura, F., & Taylor, J. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107020 · Cited by 3 · see citing works
Weinberg, O. K., & Arber, D. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-10940-9.00015-0 · Cited by 3 · see citing works
- Authors
- Shih, A. H., Chung, S. S., Dolezal, E. K., Zhang, S.-J., Abdel-Wahab, O. I., Park, C. Y., Nimer, S. D., Levine, R. L., & Klimek, V. M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Haematologica
- Published
- 2013-01-24
- Volume
- 98
- Issue
- 6
- Pages
- 908-912
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- PMC
- PMC3669447
- OpenAlex
- W2169313200
- Cited by
- 135
- References
- 31
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 9 · 2023: 8 · 2022: 8 · 2021: 9 · 2020: 15 · 2019: 13 · 2018: 11 · 2017: 14 · 2016: 12 · 2015: 9 · 2014: 14 · 2013: 4 · 2012: 2
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Haematologica (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Dana Foundation
- American Society of Hematology
- Leukemia and Lymphoma Society
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (R01CA138234, U54CA143798, P30CA008748)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- therapy-related myelodysplastic syndrome, somatic mutations, TP53 mutation, TET2, DNMT3A, ASXL1, IDH1, IDH2, EZH2, SUZ12, RBBP4, SRSF2, U2AF35, SF3B1, p53 deficiency, overall survival, prognostic factors
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Prognosis, Radiotherapy, Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
